News

Otezla (apremilast) 30mg is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), particularly for cyclic adenosine monophosphate (cAMP). It is claimed to be the first and only approved

TG6002 is a next-generation oncolytic virus (OV), which has multiple mechanisms of action. It has been engineered to combine the killing of cancer cells (oncolysis), the production of

“We are very pleased to have received the rare pediatric disease designation for LM-030 which has demonstrated safety and clinical efficacy in a Phase I/II study. Netherton Syndrome

The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Under the deal, Bridge Biotherapeutics will secure

AHF’s demand for a victim compensation fund from Gilead comes as HIV Litigation Attorneys announce its filing last Friday in Alameda County (Superior Court of California County of

In preclinical studies, the oral, small molecule candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms, and in a Phase 1 clinical trial in healthy volunteers, LYT-100 was observed to

The FDA has approved Recarbrio to treat patients 18 years of age and older who have limited or no alternative treatment options for cUTI, including pyelonephritis, caused by

As per the agreement terms, Astellas will undertake the development and commercialisation of FX-322 outside of the US, while Frequency will be responsible for the development and commercialisation

The new site builds on Kite’s existing state-of-the-art manufacturing capabilities to deliver innovative cell therapies for people with cancer, including Yescarta (axicabtagene ciloleucel), Kite’s first commercially available chimeric